Session Abstract – PMWC 2026 Silicon Valley
Track 2
Track Chair: Janusz Dutkowski, CEO, Data4Cure,
Session: AI and Omics Foundation Models Powering Translational Research
This session will explore how omics foundation models and scalable computational platforms are transforming drug discovery and translational research. Speakers will discuss how AI-driven multi-omics integration and large-scale computation across thousands of datasets enable the creation of integrated knowledge resources and predictive AI models—turning molecular data into actionable biological insights and accelerating biomarker discovery, target identification, and model selection from preclinical models to patients.
Speaker Profile
Ph.D., CEO & Founder, Data4Cure
Biography
Janusz Dutkowski is Founder and CEO of Data4Cure, Inc. a company focused on combining systems biology, machine learning and AI to facilitate continuous translation of biomedical data to knowledge. His background is in mathematics and computer science and he has been working at the intersection of mathematics, computer science and biology to develop new data driven technologies to advance the discovery of new biomarkers and precision based therapies. His research contributions include the development of methods for multiscale analysis of molecular networks and integrative methods for biomarker discovery from multidimensional data. He has co authored over 20 research papers published in scientific journals including Nature Biotechnology, Science and Cell.
Speaker Profile
Ph.D., Sr. Director, Pfizer
Biography
Dr. Jadwiga Bienkowska is a Head of Computational Biology at Pfizer, Oncology Research and Development (ORD). Dr. Bienkowska has over 20 years of experience working in Pharma and Biotech. Over her career she has built and led teams of biologists, data scientists and engineers applying at-scale Computation, Machine Learning and AI to drug development problems.At ORD Dr. Bienkowska focuses on development of breakthrough therapies for Cancer. Dr. Bienkowskas team works with biologists and clinicians on decoding multimodal data into interpretable models of mechanisms driving cancer progression and resistance to treatment. Insights generated by these models accelerate drug development through new target discovery, MOA studies, patient, and biomarker selection strategies. Dr. Bienkowska holds a PhD in Physics from the University of Chicago and completed postdoctoral training at Harvard Medical School and Dana Farber Cancer Institute.
Speaker Profile
Ph.D., Vice President, Global Data Partnerships, Champions Oncology
Biography
Alex Moreau is a senior leader at Champions Oncology, where he drives strategic partnerships and platform-enabled innovation in oncology target discovery and translational biomarker research. With over a decade of experience at the intersection of science and technology, he has led and supported oncology drug discovery programs across several world-leading CROs and advised biotechnology companies in gene editing and next-generation sequencing (NGS) through various consulting roles. Alex holds a PhD in Neuroscience from Université Paris-Saclay (France) and completed his postdoctoral research in experimental gene therapy at University College London (UK).
